Waldencast agreed on June 1, 2026 to sell Obagi Medical, the practitioner-distributed medical-grade skincare brand, to mid-market private equity firm Bridgepoint for an enterprise value of up to $460M. The structure is $366M cash at closing, $30M in vendor notes, and up to $64M of earnout tied to 2026-2027 revenue. Obagi, founded in 1988, sells through dermatologists and aesthetic practitioners across North America, Europe, Asia and the Middle East, and recently moved into FDA-approved dermal fillers through its Novaestiq acquisition, so it is no longer just a skincare line.

For a clinic, the near-term read is continuity rather than disruption. The brand keeps its founder leadership, with Michel Brousset and Hind Sebti leaving Waldencast to run Obagi under Bridgepoint, and the deal is expected to close in Q3 2026 pending regulatory approval. Waldencast is using the proceeds to repay about $178M of senior secured debt and refocus entirely on Milk Makeup, which tells you the parent is exiting the medical-aesthetics channel, not doubling down on it.

The broader signal is that practitioner-distributed skincare and filler brands keep drawing buyout money, and the line between beauty and medical aesthetics keeps blurring. Worth watching whether retail pricing or your dispensing margins shift once a new owner sets its own revenue targets.

Source: GlobeNewswire (Waldencast plc) — https://www.globenewswire.com/news-release/2026/06/01/3304174/0/en/waldencast-announces-sale-of-obagi-medical-to-bridgepoint.html